Drug repositioning meets precision in glioblastoma
Glioblastoma has a gigantic unmet medical need. Molecular knowledge has evolved substantially, including data on clonal selection with progression. Past trials for all-comers may have produced false negative results. Molecular precision at progression needs workup of new tissue, and revisiting drugs...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 2018
|
| In: |
Clinical cancer research
Year: 2018, Jahrgang: 24, Heft: 2, Pages: 256-258 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-17-2989 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1158/1078-0432.CCR-17-2989 Verlag, kostenfrei, Volltext: http://clincancerres.aacrjournals.org/content/24/2/256 
|
| Verfasserangaben: | Wolfgang Wick, Tobias Kessler |
| Zusammenfassung: | Glioblastoma has a gigantic unmet medical need. Molecular knowledge has evolved substantially, including data on clonal selection with progression. Past trials for all-comers may have produced false negative results. Molecular precision at progression needs workup of new tissue, and revisiting drugs with a focus on brain tumor penetration may yield surprises. Clin Cancer Res; 24(2); 256-8. ©2017 AACR. See related article by Byron et al., p. 295 |
|---|---|
| Beschreibung: | Gesehen am 23.04.2018 |
| Beschreibung: | Online Resource |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-17-2989 |